NOVEL SYSTEM FOR REGULATED HIGH LEVEL GENE EXPRESSION

Information

  • Research Project
  • 3507980
  • ApplicationId
    3507980
  • Core Project Number
    R44GM043638
  • Full Project Number
    2R44GM043638-02
  • Serial Number
    43638
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/27/1989 - 35 years ago
  • Project End Date
    6/30/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    7/1/1991 - 33 years ago
  • Budget End Date
    6/30/1992 - 32 years ago
  • Fiscal Year
    1991
  • Support Year
    2
  • Suffix
  • Award Notice Date
    6/27/1991 - 33 years ago
Organizations

NOVEL SYSTEM FOR REGULATED HIGH LEVEL GENE EXPRESSION

DESCRIPTION (Adapted from applicant's abstract): Numerous expression systems exist for the bioproduction of proteins in both prokaryotic and eukaryotic cells. Each system has its own set of advantages as well as shortcomings. The need remains for a mammalian cell expression system that can achieve high-level gene expression, correctly process proteins of mammalian origin, and is economical and easy to use. The aim is of this proposal is to establish a mammalian cell expression system capable of rapid and high level production of specified proteins. To this end, the use of regulatory components from the E. coli lactose operon to regulate the expression of bacteriophage T7 RNA polymerase in a single vaccinia virus-based vector system was investigated. The requirement to control T7 RNA polymerase expression was necessary since previous attempts to develop such a single virus system without regulation were unsuccessful, presumably due to the high transcriptase activity and processibility of the phage RNA polymerase causing interference with endogenous viral transcription or replication. In Phase I, a single recombinant vaccinia virus harboring both T7 RNA polymerase and T7 promoter-controlled target gene sequences under regulatory control of genetic elements from the lactose operon was successfully constructed. Induction of this system led to a higher level of target gene expression than that obtained previously using a two virus system. In Phase II, the expression parameters for this system will be further optimized. This system will be adapted to pilot-level bioreactor instrumentation leading to the bioproduction of several proteins of interest. New strategies to further refine and expand the utility of this system will be evaluated for the commercial production of proteins.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    MEDIMMUNE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    GAITHERSBURG
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20878
  • Organization District
    UNITED STATES